Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name MEG3
   Synonyms MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1
   Region GRCh38_14:100779410-100861031    Sequence
   Ensembl ENSG00000214548
   RefSeq NR_002766
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name liver cancer
   ICD-0-3 C22.0  
   Methods RT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP
   Sample liver cancer tissue, liver cancer cell line (Hep3B)
   Expression Pattern down-regulated
   Function Description

Mechanistically, MEG3 promotes the expression and maturition of miR122 which targets PKM2.Therefore,MEG3 decreases the expression and nuclear location of PKM2 dependent on miR122.Furthermore,MEG3 also inhibits CyclinD1 and C-Myc via PKM2 in liver cancer cells.On the other hand,MEG3 promotes B-catenin degradation through ubiquitin-proteasome system dependent on PTEN. Strikingly, MEG3 inhibits B-catenin activity through PKM2 reduction and PTEN increase.Significantly,we also found that excessive B-catenin abrogated the effect of MEG3 in liver cancer.MEG3 overexpression increased the PTEN 3-UTR mRNA methylation compared to control. MEG3 may be an underlying therapeutic target for LUAD functioning as ceRNAs for the regulation of miRNA-mRNA in lung adenocarcinoma.

   Pubmed ID 29449541
   Year 2018
   Title Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting B-catenin by activating PKM2 and inactivating PTEN.
   External Links
   Links for  MEG3 GenBank       HGNC       lncrnadb       Noncode
   Links for  liver cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.